Holcomb John Bradley 4

What Happened
John Bradley Holcomb, a director of MiNK Therapeutics, was awarded 4,174 stock options (reported as a derivative acquisition) on September 23, 2025. The grant shows an acquisition price of $0.00 (a typical notation for option awards), so no cash was paid by Holcomb at grant. These are awards/stock options issued under the company’s equity incentive plan.

Key Details

• Transaction date: September 23, 2025; Form 4 filed April 30, 2026 (appears late versus the 2-business-day standard filing window).
• Instrument and amount: 4,174 stock options (derivative securities) reported as an award/grant (Code A). Reported price: $0.00 (no cash paid at grant).
• Vesting: Options vest in three equal annual installments on Sept 23 of 2026, 2027 and 2028, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: Awards granted under the MiNK Therapeutics, Inc. 2021 Amended and Restated Equity Incentive Plan; vesting contingent on service through each vesting date.

Context
This was a compensation award (grant of options), not an open-market purchase or sale. Because the options vest over time and were not exercised or sold at grant, there was no immediate cash proceeds or open-market trading tied to this filing. The later filing date may reflect an administrative delay; late Form 4s can draw SEC attention but do not by themselves indicate wrongdoing.